Select Bibliography

Filter by any of these (after searching):

There are 238 items

A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0426

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer.

Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326

Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198.

Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - NCCTG-N0026

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - N0026

Computed tomography densitometry and morphology of radiofrequency ablated Stage IA non-small cell lung cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

Alexander, Erica S. , Xiong, Lillian , Baird, Grayson L. ... - - J Vasc Interv Radiol - 2020

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033

ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial

Allen, M. S. , Darling, G. E. , Decker, P. A. , Putnam, J. B. Jr ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)

Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - - Lancet Respir Med - 2018

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0010

Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)

Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - AATS - - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-140503

Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment

An, Ming-Wen , Mandrekar, Sumithra J. , Edelman, Martin J. ... - - Contemp Clin Trials - 2014

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-30203

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

Baggstrom, Maria Q. , Socinski, Mark A. , Wang, Xiaofei F. , Gu, Lin ... - - J Thorac Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607 , CALGB-70701

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105

Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105

Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study.

Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904

Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904

Bogart, Jeffrey A. , Hodgson, Lydia , Seagren, Stephen L. ... - - J Clin Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904

Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235

Bogart, Jeffrey A. , Watson, Dorothy , McClay, Edward F. ... - - Lung Cancer - 2008

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9235

Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538

Bogart, Jeffrey , Wang, Xiaofei , Masters, Gregory , Zhu, Han ... - ESMO - Ann Oncol - 2019

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-30610

Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer; Results from CALGB 159902

Boylan, Alice M. , Wang, Xiaofei F , Ko, Richard , Watson, Patricia M ... - - J. Thorac. Cardiovasc. Surg. - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-159902

LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer

Brambilla, E. , Domerg, C. , Lantuejoul, S. , Kratzke, R. ... - - J Thorac Oncol - 2012

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration

Brambilla, E. , Tsao, M. , Paris, E. , Lantuejoul, S. ... - - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

Brambilla, Elisabeth , Le Teuff, Gwénaël , Marguet, Sophie ... - - J. Clin. Oncol - 2016

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9633

Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer

Bryce, Alan H. , Mattar, Bassam , Hillman, Shauna L. , Adjei, Alex A. ... - - Am. J. Clin. Oncol. - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-0027

Phase 2 Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive-Stage Small Cell Lung Cancer, N0423

Chee, Cheng E. , Jett, James R. , Bernath, Albert M. ... - - Cancer - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0423

A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC)

Cuffe, S. , Ezzalfani, M. , Bourredjem, A. , Graziano, S. L. ... - Chicago MSTO - - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

A Pooled Exploratory Analysis of the Impact of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy (ACT) in Node Negative (N0) Non-Small Cell Lung Cancer (NSCLC).

Cuffe, S. , Graziano, S. , Bourredjem, A. , Pignon, J. P. ... - - J Thorac Oncol - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy in Node Negative Non-Small Cell Lung Cancer

Cuffe, Sinead , Bourredjem, Abderrahmane , Graziano, Stephen ... - - J Thorac Oncol - 2012

Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761

D'Cunha, J. , Wang, X. , Groth, S. S. , Vollmer, R. T. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9761

Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

Darling, G. , Allen, M. , Decker, P. , Ballman, K. , Landreneau, R. ... - AATS - American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy

Darling, Gail E. , Allen, Mark S. , Decker, Paul A. , Ballman, Karla ... - - Chest - 2011

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less Than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

Darling, Gail E. , Allen, Mark S. , Decker, Paul A. , Ballman, Karla ... - - J. Thorac. Cardiovasc. Surg. - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions

Demmy, T. L. , Gu, L. , Burkhalter, J. , Toloza, E. M. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102

Hypothetical double-consent design intervention

Demmy, T. L. , Kohman, L. J. ... - CTAS - - 2010

Abstract - No-Endpoint Endpoint - Primary Analysis - Respiratory - CALGB-30102 , CALGB-9334

Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102)

Demmy, Todd L. , Gu, Lin , Burkhalter, Jack E. , Toloza, Eric M. ... - - J Natl Compr Canc Netw - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102

Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial.

Dilts, D. M. , Adjei, A. A. , Mandrekar, S. J. , Buckner, J. C. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - NCCTG-N0723

Sublobar Resection and Iodine-125 Brachytherapy for Stage 1 NSCLC, Initial Quality Assurance Review of ACOSOG Z-4032

Dipetrillo, T. A. , Heron, D. E. , Landreneau, R. J. , Logan, D. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion

Dresler, Carolyn M. , Olak, Jemi , Herndon, James E. ... - - Chest - 2005

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9334

A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307

Dubey, Sarita , Jänne, Pasi A. , Krug, Lee , Pang, Herbert ... - - J Thorac Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30307

CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)

Dudek, A. Z. , Kindler, H. L. , Otterson, G. A. , Pang, H. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report

Dudek, A. Z. , Pang, H. , Kratzke, R. A. , Otterson, G. A. ... - - J Thorac Oncol - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601

Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901

Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901

Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial

Dupuy, D. E. , Fernando, H. , Hillman, S. , Ng, T. , Tan, A. D. ... - CHEST - Chest - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033

Radiofrequency Ablation of Stage IA NSCLC in Medically Inoperable Patients: Results from the ACOSOG Z4033 (Alliance) Trial

Dupuy, Damian E. , Fernando, Hiran C. , Hillman, Shauna , Ng, Thomas ... - - Cancer - 2015

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0528

N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2)

Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821

A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261

Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0326

A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0528

NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status

Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821

Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304

Edelman, M. J. , Hodgson, L. D. , Wang, X. , Christenson, R. H. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203

Edelman, M. J. , Watson, D. M. , Wang, X. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203

Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304

Edelman, Martin J. , Hodgson, Lydia , Wang, Xiaofei ... - - J Thorac Oncol - 2011

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304 , CALGB-30203

Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)

Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2017

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - - J. Clin. Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Edelman, Martin J , Watson, Dee , Wang, Xiaofei , Morrison, Carl ... - - J. Clin. Oncol. - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203

Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study

Fernando, H. C. , Landreneau, R. J. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 91st Annual Meeting - 2011

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

Fernando, H. C. , Landreneau, R. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 90th Annual Meeting - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - ACOSOG-Z4032

Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer

Fernando, Hiran C. , Landreneau, Rodney J. , Mandrekar, Sumithra J. ... - - J. Clin. Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non–small cell lung cancer

Fernando, Hiran C. ... - - J. Thorac. Cardiovasc. Surg. - 2012

Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Respiratory - ACOSOG-Z4099

The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea in High-risk Operable Patients; Preliminary results from the ACOSOG Z4032 Trial

Fernando, Hiran C , Landreneau, Rodney J , Mandrekar, Sumithra J ... - - J Thorac Cardiovasc Surg - 2011

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)

Fibla, J. J. , Cassivi, S. D. , Decker, P. A. , Allen, M. S. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set

Fibla, Juan J. , Cassivi, Stephen D. , Brunelli, Alessandro ... - - Lung Cancer - 2012

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)

Fibla, Juan J. , Cassivi, Stephen D. , Decker, Paul A. ... - - Eur J Cardiothorac Surg - 2013

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group.

Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation.

Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Foster, N. R. , Qi, Y. , Krook, J. E. , Kugler, J. W. , Kuross, S. A. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - N0424

Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0424

Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis

Foster, N. R. , Renfro, L. A. , Schild, S. E. , Redman, M. W. ... - - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Respiratory - Comprehensive , CALGB-9033 , CALGB-9732 , CALGB-30103 , NCCTG-862051 , NCCTG-892051 , NCCTG-932053 , ECOG-1500 , ECOG-7593 , JCOG-9511 , NCIC-BR4 , NCIC-BR8 , SWOG-S0124

Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials

Foster, Nathan R. , Mandrekar, Sumithra J. , Schild, Steven E. ... - - Cancer - 2009

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0424

Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Foster, Nathan R. , Renfro, Lindsay A. , Schild, Steven E. ... - - J Thorac Oncol - 2015

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Respiratory - CALGB-30103 , N0424 , NCCTG-932053

Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

Garces, Yolanda I , Okuno, Scott H , Schild, Steven E ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N9923

Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407

Govindan, R. , Bogart, J. A. , Wang, X. , Hodgson, L. D. ... - - J. Clin. Oncol. - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30407

A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

Govindan, R. , Bogart, J. A. , Wang, X. , Liu, D. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - CALGB-30407

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

Govindan, Ramaswamy , Bogart, Jeffrey , Stinchcombe, Thomas ... - - J Clin Oncol - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30407

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early Stage Non–Small Cell Lung Cancer

Govindan, Ramaswamy , Mandrekar, Sumithra J. , Gerber, David E. ... - - Clin. Cancer Res. - 2015

Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Respiratory - A151216

A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.

Govindan, Ramaswamy , Wang, Xiaofei , Baggstrom, Maria Q ... - - J Thorac Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30104

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA

Graziano, S. L. , Pignon, J. P. , Vollmer, R. T. , Kratzke, R. A. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901

Graziano, S. L. , Socinski, M. A. , Herndon, J. E., 2nd ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39901

LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and expression by Immunohistochemistry (IHC) in patients with resected Non-Small Cell Lung Cancer (NSCLC).

Graziano, S. , Paris, E. , Ma, X. , Pignon, J. , Hainaut, P. ... - - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

Prognostic Significance of Mucin and p53 Expression in Stage IB Non-Small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633

Graziano, Stephen L. , Gu, Lin , Wang, Xiaofei , Tatum, Arthur H. ... - - J Thorac Oncol - 2010

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9633

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA

Graziano, Stephen L. , Lacas, Benjamin , Vollmer, Robin ... - - Lung Cancer - 2013

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

Graziano, Stephen L , Herndon, James E , Socinski, Mark A ... - - J Thorac Oncol - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39901

Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC)

Green, M. R. , Miller, A. A. , Wang, X. , Gu, L. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30303

Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial

Grogan, E. , Deppen, S. , Ballman, K. , Andrade, G. , Verdail, F. ... - - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031

Accuracy of FDG-PET within the clinical practice of the ACOSOG Z4031 trial to diagnose clinical stage I NSCLC

Grogan, Eric L. , Deppen, Stephen A. , Ballman, Karla V. ... - - Ann. Thorac. Surg. - 2014

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031

LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)

Hainaut, P. , Ma, X. , Lacas, B. , Tsao, M. , Douillard, J.-Y. ... - ESMO - - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031

Harpole, D. , Ballman, K. V. , Oberg, A. L. , Whiteley, G. ... - - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031

CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

Heist, R. C. Suk , Wang, X. , Hodgson, L. D. , Otterson, G. A. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Heist, Rebecca S. , Wang, Xiaofei , Hodgson, Lydia ... - - J Thorac Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

Hensing, Thomas , Wang, Xiaofei , Kozono, David , Dudek, Arkadius ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-09

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

Hillman, S. L. , Mandrekar, S. J. , Bot, B. , Dematteo, R. P. ... - - J. Clin. Oncol. - 2010

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Respiratory - ACOSOG-Z9001 , NCCTG-97-24-51

A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials.

Huschka, Mashele M , Mandrekar, Sumithra J , Schaefer, Paul L ... - - Cancer - 2007

Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - N0021 , N0022 , NCCTG-95-20-53 , NCCTG-95-24-51 , NCCTG-95-24-52 , NCCTG-97-24-51 , NCCTG-98-24-52

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Jahan, Thierry , Gu, Lin , Kratzke, Robert , Dudek, Arkadiusz ... - - Lung Cancer - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30107

Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: Results of CALGB Protocol 39803

Jaklitsch, M. T. , Gu, L. , Demmy, T. , Harpole, D. H. ... - - J Thorac Cardiovasc Surg - 2013

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39803

Prospective Phase II Trial of Pre-Resection Thoracoscopic (VATS) Restaging Following Neoadjuvant Therapy For IIIA(N2) Non-small Cell Lung Cancer (NSCLC): Results of CALGB 39803

Jaklitsch, M. T. , Gu, L. , Harpole, D. H. , D'Amico, T. A. ... - - J. Clin. Oncol. - 2005

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39803

Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406

Janne, P. A. , Miller, V. A. , Wang, X. , Socinski, M. A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30406

Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)

Janne, P. A. , Wang, X. F. , Krug, L. M. , Hodgson, L. , Vokes, E. E. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30307

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A. , Wang, X. F. , Socinski, M. A. , Crawford, J. ... - - J. Clin. Oncol. - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30406

Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406

Janne, P. A. , Wang, X. , Socinski, M. A. , Crawford, J. , Gu, L. ... - - J Thorac Oncol - 2011

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-30406

Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study

Janne, P. , Shepherd, F. , Domerg, C. , Le Teuff, G. , Kratzke, R. ... - - Ann. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)

Jatoi, A. , Schild, S. E. , Foster, N. , Henning, G. T. ... - - Ann Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0422

Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

Jatoi, Aminah , Hillman, Shauna L , Ziegler, Katie L Allen ... - - Cancer Manag Res - 2009

Manuscript - Secondary Endpoint - Comprehensive Analysis - Respiratory - N0222 , N9921

Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study

Jett, J. R. , Bernath, A. Jr , Foster, N. , Molina, J. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0423

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

Johnson, Elizabeth A , Marks, Randolph S , Mandrekar, Sumithra J ... - - Lung Cancer - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-972451

Peak Oxygen Consumption and Long-Term All-Cause Mortality in Non-Small Cell Lung Cancer

Jones, Lee W. , Watson, Dorothy , Herndon, James E. , Eves, Neil D. ... - - Cancer - 2010

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9238 , CALGB-140803

Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206

Kelley, M. J. , Bogart, J. A. , Hodgson, L. D. , Ansari, R. H. ... - - J Thorac Oncol - 2013

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30206

CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer

Kelley, M. J. , Bogart, J. A. , Hodgson, L. D. , Ansari, R. H. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30206

Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Kent, M. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Impact of Sublobar Resection on Pulmonary Function: Long-term Results from ACOSOG Z4032 (Alliance)

Kent, Michael S. , Mandrekar, Sumithra J. , Landreneau, Rodney ... - - Ann. Thorac. Surg. - 2016

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)

Kent, Michael S. , Mandrekar, Sumithra J. , Landreneau, Rodney ... - - Ann. Thorac. Surg. - 2016

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Impact of Sublobar Resection on pulmonary function; Long-term results from Z4032 (Alliance), a randomized phase III trial

Kent, Michael , Fernando, Hiran C , Mandrekar, Sumithra ... - STSA - Ann Thoracic Surg - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Development of a Nomogram for Predicting Outcomes after Sublobar Resection for lung cancer; An Analysis from ACOSOG Z4032 (Alliance) a Randomized Trial

Kent, Michael , Mandrekar, Sumithra , Landreneau, Rodney ... - AATS - - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238

Kohman, L. J. , Watson, D. M. , Herndon, J. E. 2nd , Eves, N. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-140803 , CALGB-9238

Biopsy first: Lessons learned from CALGB 140503

Kohman, Leslie J. , Gu, Lin , Altorki, Nasser , Scalzetti, Ernest ... - - J. Thorac. Cardiovasc. Surg. - 2017

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - A081202 , CALGB-140503 , CALGB-580602

Surgeon Error In Predicting Stage I Non-Small Cell Lung Cancer (NSCLC) Is A Major Factor Precluding Randomization In CALGB 140503 (Alliance)

Kohman, Leslie J. , Gu, Lin , Altorki, Nasser , Veit, Linda J. ... - AATS - - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-140503

Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).

Kozono, David E. , Salama, Joseph Kamel , Stinchcombe, Tom ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-07

Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).

Kozono, David E. , Stinchcombe, Thomas , Salama, Joseph K. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-07

Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer?

Kozower, Benjamin D , Meyers, Bryan F , Reed, Carolyn E ... - - Ann. Thorac. Surg. - 2008

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0050

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

Kratzke, Robert A , Wang, Xiaofei , Wong, Long , Kratzke, Marian G ... - - J Thorac Oncol - 2008

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-159904

Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2: CALGB 30402

Lilenbaum, R. C. , Wang, X. , Gu, L. , Kirshner, J. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30402

A Phase II Study Of Induction Chemotherapy Followed By Thoracic Radiotherapy (TRT) And Erlotinib In Poor-risk Stage III Non-small Cell Lung Cancer (NSCLC): Initial Results Of CALGB 30605 And RTOG 0972

Lilenbaum, R. , Samuels, M. , Kong, F. , Wang, X. , Janne, P. ... - - J Thorac Oncol - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30605

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730).

Lilenbaum, Rogerio C , Herndon, James E , List, Marcy A ... - - J. Clin. Oncol. - 2005

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9730

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

Lilenbaum, Rogerio , Samuels, Michael , Wang, Xiaofei ... - - J Thorac Oncol - 2015

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30605

Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

Lilenbaum, Rogerio , Wang, Xiaofei , Gu, Lin , Kirshner, Jeffrey ... - - J Clin Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30402

Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial.

Liptay, Michael J , D'amico, Thomas A , Nwogu, Chumy , Demmy, Todd L ... - - J Thorac Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-140203

Preoperative exercise VO2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.

Loewen, Gregory M , Watson, Dorothy , Kohman, Leslie ... - - J Thorac Oncol - 2007

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9238

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Ma, Xiaoli , Le Teuff, Gwénaël , Lacas, Benjamin , Tsao, Ming Sound ... - - J Thorac Oncol - 2016

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Respiratory - CALGB-150802 , CALGB-9633

Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation

Mandrekar, S. J. , Hillman, S. L. , Ziegler, K. L. Allen ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: a joint North Center Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation

Mandrekar, S. J. , Qi, Y. , Allen-Ziegler, K. , Hillman, S. L. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer

Mandrekar, S. , Hillman, S. , Jatoi, A. , Jett, J. , Schild, S. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer

Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012

Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Respiratory - N0424

Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)

Martin, Linda W. , D’Cunha, Jonathan , Wang, Xiaofei , Herzan, Debra ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Respiratory - C9761

A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531

Masters, Gregory A. , Wang, Xiaofei , Hodgson, Lydia , Shea, Thomas ... - - Lung Cancer - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9531

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Mauguen, A. , Pignon, J. P. , Burdett, S. , Domerg, C. , Fisher, D. ... - - Lancet Oncol. - 2013

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Respiratory - CALGB-8831 , CALGB-9310 , CALGB-9633 , NCCTG-892052 , NCCTG-902451 , NCCTG-942452

A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).

McClay, Edward F , Bogart, Jeff , Herndon, James E , Watson, Dee ... - - Am. J. Clin. Oncol. - 2005

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9235

Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222

McKean, Heidi , Stella, Philip J. , Hillman, Shauna L. ... - - Cancer Invest. - 2011

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - N0222

The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial.

Meyers, Bryan F , Downey, Robert J , Decker, Paul A ... - - J. Thorac. Cardiovasc. Surg. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0060

Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002

Miller, A. A. , Bogart, J. A. , Watson, D. M. , Wang, X. F. ... - - J. Clin. Oncol. - 2005

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30002

A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Miller, Antonius A. , Pang, Herbert , Hodgson, Lydia ... - - J Thorac Oncol - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30602

A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Miller, Antonius A. , Pang, Herbert , Hodgson, Lydia ... - - J Thorac Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30602

Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.

Miller, Antonius A , Wang, Xiaofei F , Bogart, Jeffrey A ... - - J Thorac Oncol - 2007

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30002

Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).

Miller, Antonius A , Wang, Xiaofei F , Gu, Lin , Hoffman, Philip ... - - J Thorac Oncol - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30303

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study

Molina, J. R. , Dy, G. K. , Foster, N. R. , Ziegler, Allen ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0626

A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study

Molina, J. R. , Mandrekar, S. J. , Dy, G. , Aubry, M. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0923

A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study

Molina, J. R. , Mandrekar, S. J. , Ziegler, K. L. Allen ... - - J Thorac Oncol - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0623

NCCTG Phase II Trial (N0621) of the SRC inhibitor AZD0530 after 4 cycles of cytoreductive chemotherapy for patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Molina, Julian R. , Foster, Nathan R. , Nelson, Garth D. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - N0621

A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Molina, Julian R. , Foster, Nathan R. , Reungwetwattana, Thanyanan ... - - Lung Cancer - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0621

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

Niell, Harvey B , Herndon, James E , Miller, Antonius A ... - - J. Clin. Oncol. - 2005

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - C9732

VATS Lobectomy Has Better Peri-operative Outcomes than Open Lobectomy: Ancillary Analysis of CALGB 140202 (Alliance)

Nwogu, C. E. , D’cunha, J. , Pang, H. , Gu, L. , Wang, X. ... - STS - - 2014

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-140202

VATS Lobectomy Has Better Peri-operative Outcomes than open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance)

Nwogu, Chukwumere E. , D’Cunha, Jonathan , Pang, Herbert , Gu, Lin ... - - Ann. Thorac. Surg. - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-31001 , CALGB-140202

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

Okuno, Scott H , Delaune, Robert , Sloan, Jeff A , Foster, Nathan R ... - - Cancer - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0021

Survival implications of variation in the thoroughness of pathologic lymph node examination in American College of Surgeons Oncology Group Z0030 (Alliance)

Osarogiagbon, Raymond U. , Decker, Paul A. , Ballman, Karla ... - - Ann. Thorac. Surg. - 2016

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Survival implications of variation in the lymph node (LN) count in ACOSOG Z0030 (Alliance)

Osarogiagbon, Raymond U. , Decker, Paul , Ballman, Karla ... - IASLC (WCLC) - J Thorac Oncol - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Phase II Study of the HDAC Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (CALGB 30304)

Otterson, G.A. , Hodgson, L. , Pang, H. ... - - J Thorac Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30304

Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216)

Oxnard, Geoffrey R. , Mandrekar, Sumithra , Hillman, Shauna ... - IASLC (WCLC) - J Thorac Oncol - 2018

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - A151216

Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups

Pang, H. , Gu, L. , Richards, W. , Crawford, J. , Green, M. , Vokes, E. ... - - Cancer Res. - 2013

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - C8834 , C8836 , C8931 , C8932 , C9132 , C9532 , CALGB-140202 , CALGB-140203 , CALGB-30203 , CALGB-30303 , CALGB-30402 , CALGB-30406 , CALGB-30506 , CALGB-30704 , CALGB-39802 , CALGB-39809 , CALGB-39904 , CALGB-9238 , CALGB-9335 , CALGB-9633 , CALGB-9730 , CALGB-9731 , CALGB-9761

Validation of the CALGB and EORTC Prognostic Models for Mesothelioma Based on Multiple CALGB Trials (Alliance)

Pang, Herbert , Hodgson, Lydia , Kratzke, Robert , Crawford, Jeffrey ... - IASLC (WCLC) - J Thoracic Oncol - 2013

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Respiratory - CALGB-8435 , CALGB-8638 , CALGB-8833 , CALGB-8933 , CALGB-9031 , CALGB-9131 , CALGB-9234 , CALGB-9530 , CALGB-9631 , CALGB-9733 , CALGB-30101 , CALGB-30107 , CALGB-30307 , CALGB-30601 , CALGB-39807

Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)

Pang, Herbert , Yan, Kang , Kratzke, Robert , Stinchcombe, Thomas ... - IASLC (WCLC) - J Thorac Oncol - 2017

Abstract - No-Endpoint Endpoint - Meta-Analysis Analysis - Respiratory - CALGB-30101 , CALGB-30107 , CALGB-30307 , CALGB-30601 , CALGB-39807 , CALGB-8435 , CALGB-8638 , CALGB-8833 , CALGB-8933 , CALGB-9031 , CALGB-9131 , CALGB-9234 , CALGB-9530 , CALGB-9631 , CALGB-9733

A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).

Parikh, Kaushal , Mandrekar, Sumithra J , Allen-Ziegler, Katie ... - - Oncologist - 2019

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0623

Updated analysis of a Phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734

Perry, M. C. , Kohman, L. , Bonner, J. , Gu, L. , Wang, X. , Vokes, E. ... - - J. Clin. Oncol. - 2005

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Respiratory - CALGB-9734

A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.

Perry, Michael C , Kohman, Leslie J , Bonner, James A , Gu, Lin ... - - Clin Lung Cancer - 2007

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - C9734

LACE-Bio: Cross-validation and Pooled Analyses of the Putative Prognostic/Predictive Biomarkers p27, p16 and cyclin E in IALT, ANITA, JBR10 and CALGB 9633

Pirker, R. , Rousseau, V. , Paris, E. , Tsao, M. S. , Aviel-Ronen, S. ... - - J Thorac Oncol - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials

Qi, Y. , Dy, G. K. , Nelson, G. D. , Schild, S. E. , Mandrekar, S. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

Qi, Y. , Ziegler, K. L. Allen , Hillman, S. L. , Redman, M. W. ... - - Cancer - 2012

Manuscript - Secondary-not-in-original Endpoint -